One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2021-149115
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2021 |
Affiliation: The University of Texas Southwestern Medical Center, The Ohio State University, Leukemia and Lymphoma Society, University of Chicago, University of Florida, University of Cincinnati, University of Kansas, Memorial Sloan Kettering Cancer Center, Mayo Clinic, University of Maryland, Baltimore, Emory University, University of California, Los Angeles, University of North Carolina at Chapel Hill, University of California, San Francisco, University of Utah, Huntsman Cancer Institute, State Library of Ohio, UPMC Hillman Cancer Center, Oregon Health & Science University
Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
